Anastrozole increases predicted adult height of short adolescent males treated with growth hormone

A randomized, placebo-controlled, multicenter trial for one to three years

Nelly Mauras, Lilliam Gonzalez De Pijem, Helen Y. Hsiang, Paul Desrosiers, Robert Rapaport, I. David Schwartz, Karen Oerter Klein, Ravinder Jit Singh, Anna Miyamoto, Kim Bishop

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Context: The process of epiphyseal fusion during puberty is regulated by estrogen, even in males. Objective: Our objective was to investigate whether anastrozole, a potent aromatase inhibitor, could delay bone age acceleration and increase predicted adult height in adolescent boys with GH deficiency. Methods: Fifty-two adolescent males with GH deficiency treated with GH were randomized to cotreatment with anastrozole or placebo daily for up to 36 months. Results: Fifty subjects completed 12 months, 41 completed 24 months, and 28 completed 36 months. Linear growth was comparable between groups; however, there was a significantly slower increase in bone age advancement from baseline in the anastrozole group vs. placebo group after 2yr (+1.8 ± 0.1 vs. +2.7 ± 0.1 yr, P < 0.0001) and after 3 yr (+2.5 ± 0.2 vs. +4.1 ± 0.1 yr, P<0.0001). This resulted in a net increase in predicted adult height of +4.5 ± 1.2 cm in the anastrozole group at 24 months and +6.7 ± 1.4 cm at 36 months as compared with a 1-cm gain at both time points in the placebo group. Estradiol and estrone concentrations increased less in the anastrozole group compared with placebo group. All boys on the aromatase inhibitor had normal tempo of virilization. Safety data, including glucose, and plasma lipid concentrations were comparable between groups. Conclusions: Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2-3 yr. This treatment offers an alternative in promoting growth in GH-deficient boys in puberty. Long-term follow up is needed to elucidate fully the safety and efficacy of this approach.

Original languageEnglish (US)
Pages (from-to)823-831
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume93
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Growth Hormone
Multicenter Studies
Placebos
Aromatase Inhibitors
Puberty
Bone
Virilism
Safety
Bone and Bones
Estrone
Growth
anastrozole
Estradiol
Estrogens
Fusion reactions
Lipids
Plasmas
Glucose
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Anastrozole increases predicted adult height of short adolescent males treated with growth hormone : A randomized, placebo-controlled, multicenter trial for one to three years. / Mauras, Nelly; De Pijem, Lilliam Gonzalez; Hsiang, Helen Y.; Desrosiers, Paul; Rapaport, Robert; Schwartz, I. David; Klein, Karen Oerter; Singh, Ravinder Jit; Miyamoto, Anna; Bishop, Kim.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 93, No. 3, 03.2008, p. 823-831.

Research output: Contribution to journalArticle

Mauras, Nelly ; De Pijem, Lilliam Gonzalez ; Hsiang, Helen Y. ; Desrosiers, Paul ; Rapaport, Robert ; Schwartz, I. David ; Klein, Karen Oerter ; Singh, Ravinder Jit ; Miyamoto, Anna ; Bishop, Kim. / Anastrozole increases predicted adult height of short adolescent males treated with growth hormone : A randomized, placebo-controlled, multicenter trial for one to three years. In: Journal of Clinical Endocrinology and Metabolism. 2008 ; Vol. 93, No. 3. pp. 823-831.
@article{b92fb49f9a4f4f0094fb1fed12f71581,
title = "Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: A randomized, placebo-controlled, multicenter trial for one to three years",
abstract = "Context: The process of epiphyseal fusion during puberty is regulated by estrogen, even in males. Objective: Our objective was to investigate whether anastrozole, a potent aromatase inhibitor, could delay bone age acceleration and increase predicted adult height in adolescent boys with GH deficiency. Methods: Fifty-two adolescent males with GH deficiency treated with GH were randomized to cotreatment with anastrozole or placebo daily for up to 36 months. Results: Fifty subjects completed 12 months, 41 completed 24 months, and 28 completed 36 months. Linear growth was comparable between groups; however, there was a significantly slower increase in bone age advancement from baseline in the anastrozole group vs. placebo group after 2yr (+1.8 ± 0.1 vs. +2.7 ± 0.1 yr, P < 0.0001) and after 3 yr (+2.5 ± 0.2 vs. +4.1 ± 0.1 yr, P<0.0001). This resulted in a net increase in predicted adult height of +4.5 ± 1.2 cm in the anastrozole group at 24 months and +6.7 ± 1.4 cm at 36 months as compared with a 1-cm gain at both time points in the placebo group. Estradiol and estrone concentrations increased less in the anastrozole group compared with placebo group. All boys on the aromatase inhibitor had normal tempo of virilization. Safety data, including glucose, and plasma lipid concentrations were comparable between groups. Conclusions: Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2-3 yr. This treatment offers an alternative in promoting growth in GH-deficient boys in puberty. Long-term follow up is needed to elucidate fully the safety and efficacy of this approach.",
author = "Nelly Mauras and {De Pijem}, {Lilliam Gonzalez} and Hsiang, {Helen Y.} and Paul Desrosiers and Robert Rapaport and Schwartz, {I. David} and Klein, {Karen Oerter} and Singh, {Ravinder Jit} and Anna Miyamoto and Kim Bishop",
year = "2008",
month = "3",
doi = "10.1210/jc.2007-1559",
language = "English (US)",
volume = "93",
pages = "823--831",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Anastrozole increases predicted adult height of short adolescent males treated with growth hormone

T2 - A randomized, placebo-controlled, multicenter trial for one to three years

AU - Mauras, Nelly

AU - De Pijem, Lilliam Gonzalez

AU - Hsiang, Helen Y.

AU - Desrosiers, Paul

AU - Rapaport, Robert

AU - Schwartz, I. David

AU - Klein, Karen Oerter

AU - Singh, Ravinder Jit

AU - Miyamoto, Anna

AU - Bishop, Kim

PY - 2008/3

Y1 - 2008/3

N2 - Context: The process of epiphyseal fusion during puberty is regulated by estrogen, even in males. Objective: Our objective was to investigate whether anastrozole, a potent aromatase inhibitor, could delay bone age acceleration and increase predicted adult height in adolescent boys with GH deficiency. Methods: Fifty-two adolescent males with GH deficiency treated with GH were randomized to cotreatment with anastrozole or placebo daily for up to 36 months. Results: Fifty subjects completed 12 months, 41 completed 24 months, and 28 completed 36 months. Linear growth was comparable between groups; however, there was a significantly slower increase in bone age advancement from baseline in the anastrozole group vs. placebo group after 2yr (+1.8 ± 0.1 vs. +2.7 ± 0.1 yr, P < 0.0001) and after 3 yr (+2.5 ± 0.2 vs. +4.1 ± 0.1 yr, P<0.0001). This resulted in a net increase in predicted adult height of +4.5 ± 1.2 cm in the anastrozole group at 24 months and +6.7 ± 1.4 cm at 36 months as compared with a 1-cm gain at both time points in the placebo group. Estradiol and estrone concentrations increased less in the anastrozole group compared with placebo group. All boys on the aromatase inhibitor had normal tempo of virilization. Safety data, including glucose, and plasma lipid concentrations were comparable between groups. Conclusions: Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2-3 yr. This treatment offers an alternative in promoting growth in GH-deficient boys in puberty. Long-term follow up is needed to elucidate fully the safety and efficacy of this approach.

AB - Context: The process of epiphyseal fusion during puberty is regulated by estrogen, even in males. Objective: Our objective was to investigate whether anastrozole, a potent aromatase inhibitor, could delay bone age acceleration and increase predicted adult height in adolescent boys with GH deficiency. Methods: Fifty-two adolescent males with GH deficiency treated with GH were randomized to cotreatment with anastrozole or placebo daily for up to 36 months. Results: Fifty subjects completed 12 months, 41 completed 24 months, and 28 completed 36 months. Linear growth was comparable between groups; however, there was a significantly slower increase in bone age advancement from baseline in the anastrozole group vs. placebo group after 2yr (+1.8 ± 0.1 vs. +2.7 ± 0.1 yr, P < 0.0001) and after 3 yr (+2.5 ± 0.2 vs. +4.1 ± 0.1 yr, P<0.0001). This resulted in a net increase in predicted adult height of +4.5 ± 1.2 cm in the anastrozole group at 24 months and +6.7 ± 1.4 cm at 36 months as compared with a 1-cm gain at both time points in the placebo group. Estradiol and estrone concentrations increased less in the anastrozole group compared with placebo group. All boys on the aromatase inhibitor had normal tempo of virilization. Safety data, including glucose, and plasma lipid concentrations were comparable between groups. Conclusions: Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2-3 yr. This treatment offers an alternative in promoting growth in GH-deficient boys in puberty. Long-term follow up is needed to elucidate fully the safety and efficacy of this approach.

UR - http://www.scopus.com/inward/record.url?scp=40849085155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849085155&partnerID=8YFLogxK

U2 - 10.1210/jc.2007-1559

DO - 10.1210/jc.2007-1559

M3 - Article

VL - 93

SP - 823

EP - 831

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -